ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, has announced the acquisition of Exco InTouch, a leading provider of patient engagement, data capture and digital health solutions.
The combined organization will provide the biopharmaceutical industry with the most advanced and comprehensive choice for electronic clinical outcome assessments (eCOA), patient engagement and digital health.
As a result, ERT will enable sponsors to turn to a single strategic partner to support the full clinical development-to-commercialization spectrum – from early phase to in market, from the simplest to the most complex – and minimize their risk, run safer and more efficient programs, and get new clinical treatments to patients more quickly.
“With this acquisition, we have combined our science-driven solutions that are delivered across every modality with patient-driven solutions that open up the BYOD (Bring Your Own Device) market to create a seamless approach to eCOA, patient engagement and digital health,” said James Corrigan, President and CEO, ERT.
“Exco InTouch has a great history of innovation, and since its inception has made significant contributions to the eClinical landscape. We are delighted to welcome them to the ERT team, and look forward to working together to deliver market-leading offerings that solve our clients’ most complex challenges.”
“ERT is the eCOA industry leader with a strong history in developing novel eClinical products and technologies to minimize risk and uncertainty in clinical research. They were an obvious choice when we were assessing our strategic business development options,” said Tim Davis, Founder and CEO, Exco InTouch.
“Now biopharmaceutical companies can turn to one company for all of their eCOA, patient engagement and commercialization needs, with confidence that their programs will have the right level of experience and expertise, anticipatory oversight, and adaptive problem solving required to ensure the most reliable results.”
Financial terms of the transaction were not disclosed.